Telix (TLX) | Financial Analysis & Statements
Telix Pharmaceuticals Ltd. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
1.2B
Total Liabilities
748.6M
Shareholders Equity
415.4M
Debt to Equity
1.80
Cash Flow Metrics
Free Cash Flow
-13.3M
Revenue & Profitability Trend
Annual Income Flow
2025
Telix Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 803.8M | 516.6M | 333.0M | 108.9M | 3.3M |
| Cost of Goods Sold | 377.4M | 180.4M | 123.4M | 44.3M | 1.7M |
| Gross Profit | 426.4M | 336.2M | 209.5M | 64.6M | 1.6M |
| Gross Margin % | 53.1% | 65.1% | 62.9% | 59.3% | 48.0% |
| Operating Expenses | |||||
| Research & Development | 171.2M | 127.9M | 85.3M | 54.9M | 22.7M |
| Selling, General & Administrative | 237.1M | 152.2M | 89.4M | 59.5M | 27.1M |
| Other Operating Expenses | -12.0K | 458.0K | -130.0K | 691.9K | 14.0M |
| Total Operating Expenses | 408.4M | 280.6M | 174.6M | 115.1M | 63.8M |
| Operating Income | 18.1M | 55.6M | 35.0M | -50.5M | -65.7M |
| Operating Margin % | 2.2% | 10.8% | 10.5% | -46.3% | -2,017.2% |
| Non-Operating Items | |||||
| Interest Income | 5.8M | 7.2M | 671.0K | 484 | - |
| Interest Expense | 40.4M | 24.2M | 8.9M | 4.5M | 3.5M |
| Other Non-Operating Income | 11.7M | -407.0K | -24.0M | -12.1M | 15.7M |
| Pre-tax Income | -5.3M | 37.9M | 2.6M | -47.8M | -53.5M |
| Income Tax | 1.9M | 4.2M | -1.6M | 2.6M | 29.9K |
| Effective Tax Rate % | 0.0% | 11.2% | -62.2% | 0.0% | 0.0% |
| Net Income | -7.1M | 33.7M | 4.2M | -50.4M | -53.6M |
| Net Margin % | -0.9% | 6.5% | 1.3% | -46.3% | -1,643.7% |
| Key Metrics | |||||
| EBITDA | 24.7M | 62.8M | 35.5M | -50.5M | -47.7M |
| EPS (Basic) | $-0.02 | $0.10 | $0.01 | $-0.23 | $-0.29 |
| EPS (Diluted) | $-0.02 | $0.10 | $0.01 | $-0.23 | $-0.29 |
| Basic Shares Outstanding | 319181000 | 331226000 | 228163346 | 221206606 | 187724337 |
| Diluted Shares Outstanding | 319181000 | 331226000 | 228163346 | 221206606 | 187724337 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Telix Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 141.9M | 440.0M | 84.3M | 56.4M | 14.7M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 129.2M | 86.9M | 44.0M | 19.1M | 485.6K |
| Inventory | 37.1M | 23.6M | 12.7M | 4.1M | 2.3M |
| Other Current Assets | - | - | 12.4M | 3.2M | 947.9K |
| Total Current Assets | 330.3M | 570.1M | 158.7M | 83.9M | 31.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 20.9M | 9.2M | 4.1M |
| Goodwill | 791.8M | 324.4M | 77.4M | 31.2M | 39.8M |
| Intangible Assets | 393.8M | 191.3M | 51.0M | 25.9M | 34.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 121.6M | 75.0M | 14.7M | 2.1M | 141.0K |
| Total Non-Current Assets | 833.7M | 370.3M | 118.6M | 39.8M | 41.4M |
| Total Assets | 1.2B | 940.4M | 277.3M | 123.7M | 73.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 88.8M | 49.7M | 16.0M | 8.1M | 7.9M |
| Short-term Debt | 18.7M | 13.3M | 1.1M | 310.5K | 420.4K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 11.5M | 53.2M | 25.4M | 2.4M | 4.1M |
| Total Current Liabilities | 231.6M | 205.1M | 111.4M | 41.4M | 25.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 448.4M | 346.9M | 11.2M | 4.7M | 1.3M |
| Deferred Tax Liabilities | 44.7M | 5.8M | 0 | - | - |
| Other Non-Current Liabilities | 14.2M | 18.8M | 38.0M | 10.9M | 15.3M |
| Total Non-Current Liabilities | 517.0M | 382.4M | 63.2M | 43.5M | 46.3M |
| Total Liabilities | 748.6M | 587.4M | 174.6M | 84.9M | 71.6M |
| Equity | |||||
| Common Stock | 0 | 0 | 0 | 179.7M | 113.6M |
| Retained Earnings | -154.5M | -152.9M | -187.1M | -132.2M | -115.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 415.4M | 352.9M | 102.6M | 38.8M | 1.4M |
| Key Metrics | |||||
| Total Debt | 467.1M | 360.2M | 12.3M | 5.1M | 1.7M |
| Working Capital | 98.7M | 365.0M | 47.3M | 42.5M | 6.4M |
Balance Sheet Composition
Telix Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | - | - | - | - | - |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 0 | 0 | 0 | 0 | 0 |
| Operating Cash Flow | - | - | - | - | - |
| Investing Activities | |||||
| Capital Expenditures | -25.7M | -9.1M | -6.3M | -3.4M | -890.7K |
| Acquisitions | -229.0M | -23.2M | -995.0K | -471.4K | - |
| Investment Purchases | -892.0K | -32.9M | -8.7M | 0 | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -267.8M | -73.6M | -16.0M | -4.9M | -1.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | -5.6M | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 529.0K | 427.9M | 4.2M | 1.5M | - |
| Debt Repayment | -6.1M | -2.1M | -1.3M | -868.7K | -226.2K |
| Financing Cash Flow | -3.7M | 416.8M | 5.5M | 78.9M | 1.9M |
| Free Cash Flow | -61.1M | 5.3M | 7.2M | -37.7M | -40.4M |
| Net Change in Cash | -271.6M | 343.2M | -10.5M | 74.0M | 79.8K |
Cash Flow Trend
Telix Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
362.50
Forward P/E
41.34
Price to Book
8.31
Price to Sales
4.29
PEG Ratio
41.34
Profitability Ratios
Profit Margin
-0.89%
Operating Margin
1.94%
Return on Equity
-1.86%
Return on Assets
1.15%
Financial Health
Current Ratio
1.43
Debt to Equity
112.45
Beta
0.61
Per Share Data
EPS (TTM)
$-0.02
Book Value per Share
$1.23
Revenue per Share
$2.38
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TLX | 3.6B | 362.50 | 8.31 | -1.86% | -0.89% | 112.45 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






